Medicinova (MNOV) CEO Issues Letter to Shareholders

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. CRWV
2. NVDA
3. SPY
4. BAC
5. BLK
6. AA
7. RKLB
8. RXRX
9. NOW
10. CAT

Go back to Medicinova (MNOV) CEO Issues Letter to Shareholders

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

November 19, 2024 9:00 AM EST

NIH-funded Phase 2-3 ALS Expanded Access study expands reach of MediciNovas ongoing COMBAT-ALS trial and provides illustration of Companys development strategy

LA JOLLA, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) focused on development of novel anti-inflammatory treatments for neurodegenerative diseases, malignant brain cancers, and metabolic diseases, provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D., Ph.D.:

... More